Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496)
:2496
Want to see HK:2496 full AI Analyst Report?
2496 Stock Chart & Stats
HK$7.86
-HK$0.01(-0.13%)
At close: 4:00 PM EST
HK$7.86
-HK$0.01(-0.13%)
Day’s Range― - ―
52-Week RangeHK$3.60 - HK$8.50
Previous CloseN/A
Volume2.20K
Average Volume (3M)933.00
Market Cap
HK$814.17M
Enterprise ValueHK$719.78M
Total Cash (Recent Filing)HK$100.11M
Total Debt (Recent Filing)HK$127.81M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding179,479,110
10 Day Avg. Volume80
30 Day Avg. Volume933
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)-26.32
Price to Sales (P/S)21.44
P/FCF Ratio-62.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnMaterial reduction in operating and free cash burn in 2025 meaningfully extends runway versus 2024. If sustained, tighter spending and working-capital relief improve financing flexibility, lowering near-term funding pressure and enabling more time to execute remediation or commercial plans.
Demonstrated High Gross-margin PotentialThe company previously delivered very high gross margins, indicating underlying product or pricing leverage. That historical margin capability suggests that if revenue and product mix recover, the business can regain strong unit economics and scalability, improving long-term cash generation.
Improving Loss TrajectoryProfitability has trended toward improvement from earlier extreme losses, signaling management has begun to rein in costs or stabilize operations. A sustained improvement path increases the credibility of a recovery plan and reduces cumulative cash drain over the medium term.
Bears Say
Sharp Revenue DeclineA greater-than-50% revenue drop in a single year represents a severe demand, execution, or product issue that undermines scale economics. Prolonged revenue weakness impedes margin recovery, limits operating leverage, and increases reliance on external capital to sustain R&D and operations.
Negative Shareholders' EquityNegative equity is a material balance-sheet red flag that constrains borrowing capacity and elevates solvency risk. It heightens the probability of dilutive recapitalizations or creditor-driven restructurings, making long-term financing and strategic flexibility more difficult and costly.
Persistent Cash-flow DeficitsDespite 2025 improvement, the business remains cash-flow negative historically, requiring ongoing external funding. Persistent deficits limit the company's ability to self-fund R&D, commercial scaling, or debt repayment, increasing dilution and execution risk if capital access tightens.
Wuhan YZY Biopharma Co., Ltd. Class H News
2496 FAQ
What was Wuhan YZY Biopharma Co., Ltd. Class H’s price range in the past 12 months?
Wuhan YZY Biopharma Co., Ltd. Class H lowest stock price was HK$3.60 and its highest was HK$8.50 in the past 12 months.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s market cap?
Wuhan YZY Biopharma Co., Ltd. Class H’s market cap is HK$814.17M.
When is Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date?
Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 76 days.
How were Wuhan YZY Biopharma Co., Ltd. Class H’s earnings last quarter?
Wuhan YZY Biopharma Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported -HK$0.146 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.146.
Is Wuhan YZY Biopharma Co., Ltd. Class H overvalued?
According to Wall Street analysts Wuhan YZY Biopharma Co., Ltd. Class H’s price is currently Overvalued.
Does Wuhan YZY Biopharma Co., Ltd. Class H pay dividends?
Wuhan YZY Biopharma Co., Ltd. Class H does not currently pay dividends.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate?
Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wuhan YZY Biopharma Co., Ltd. Class H have?
Wuhan YZY Biopharma Co., Ltd. Class H has 179,479,110 shares outstanding.
What happened to Wuhan YZY Biopharma Co., Ltd. Class H’s price movement after its last earnings report?
Wuhan YZY Biopharma Co., Ltd. Class H reported an EPS of -HK$0.146 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuhan YZY Biopharma Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2496
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuhan YZY Biopharma Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.51%
12-Months-Change
Fundamentals
Return on Equity
485.24%
Trailing 12-Months
Asset Growth
-31.62%
Trailing 12-Months
Company Description
Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Technical Analysis
Brii Biosciences Limited
―
3D Medicines, Inc.
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Sunho Biologics,Inc.
―